Sarcomatoid non-small cell lung cancer (s-NSCLC), a rare histological variant accounting for approximately 0.4% of all pulmonary malignancies, is pathologically defined by the coexistence of epithelial and mesenchymal components [1, 2]. As a highly heterogeneous subtype, s-NSCLC is frequently diagnosed...
In 2020 lung cancer was the second most common cancer and the leading cause for cancer death [1]. Surgery, if possible, is known as the first choice of treatment. Lobectomy or segmentectomy are the standard procedures for anatomical resection. They are mainly performed by video-assisted thoracoscopic...
Lung cancer is the leading cause of cancer-related death and the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. In the Middle East and North Africa (MENA) region, lung cancer ranks second in incidence and cancer mortality,...
The first-line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on the positive PFS and OS results from the FLAURA study. This paper reviews and...
According to the 2020 GLOBOCAN report, lung cancer is the second most commonly diagnosed cancer worldwide, accounting for 11.4% of new cases, and it has the highest mortality rate, responsible for 18% of cancer-related deaths [1]. Non-small cell lung cancer (NSCLC) represents approximately 85% of these...